• 1
    Peleg AY, Weerarathna T, McCarthy JS, Davis TM. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev 2007; 23:313.
  • 2
    Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus. N Engl J Med 1999; 341:19061912.
  • 3
    Pozzilli P, Leslie RD. Infections and diabetes: mechanisms and prospects for prevention. Diabet Med 1994; 11:935941.
  • 4
    Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 2003; 26:510513.
  • 5
    Boyko EJ, Fihn SD, Scholes D, Abraham L, Monsey B. Risk of urinary tract infection and asymptomatic bacteriuria among diabetic and nondiabetic postmenopausal women. Am J Epidemiol 2005; 161:557564.
  • 6
    Muller LM, Gorter KJ, Hak E et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 2005; 41:281288.
  • 7
    Bertoni AG, Saydah S, Brancati FL. Diabetes and the risk of infection-related mortality in the US. Diabetes Care 2001; 24:10441049.
  • 8
    Marrie TJ. Bacteraemic pneumococcal pneumonia: a continuously evolving disease. J Infect 1992; 24:247255.
  • 9
    Watanakunakorn C, Bailey TA. Adult bacteremic pneumococcal pneumonia in a community teaching hospital, 1992–1996. A detailed analysis of 108 cases. Arch Intern Med 1997; 157:19651971.
  • 10
    Thomsen RW, Hundborg HH, Lervang HH, Johnsen SP, Sorensen HT, Schonheyder HC. Diabetes and outcome of community-acquired pneumococcal bacteremia: a 10-year population-based cohort study. Diabetes Care 2004; 27:7076.
  • 11
    The Diabetes Control and Complications Trial Research Group (DCCT). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med 1993; 329:977986.
  • 12
    The Diabetes Control and Complications Trial Research Group (DCCT). Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:26432653.
  • 13
    UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:854865.
  • 14
    McMahon MM, Bistrian BR. Host defenses and susceptibility to infection in patients with diabetes mellitus. Infect Dis Clin North Am 1995; 9:19.
  • 15
    Benfield T, Jensen JS, Nordestgaard BG. Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome. Diabetologia 2007; 50:549554.
  • 16
    Butler SO, Btaiche IF, Alaniz C. Relationship between hyperglycemia and infection in critically ill patients. Pharmacotherapy 2005; 25:963976.
  • 17
    Latham R, Lancaster AD, Covington JF, Pirolo JS, Thomas CS. The association of diabetes and glucose control with surgical-site infections among cardiothoracic surgery patients. Infect Control Hosp Epidemiol 2001; 22:607612.
  • 18
    Baynes JW. Role of oxidative stress in the development of complications in diabetes. Diabetes 1991; 40:405412.
  • 19
    Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001; 17:189212.
  • 20
    Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414:813820.
  • 21
    Ceriello A, Bortolotti N, Crescentini A et al. Antioxidant defenses are reduced during the oral glucose tolerance test in normal and non-insulin-dependent diabetic subjects. Eur J Clin Invest 1998; 28:329333.
    Direct Link:
  • 22
    Vincent AM, Russell JW, Low P, Feldman EL. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 2004; 25:612628.
  • 23
    Rubinstein R, Genaro AM, Motta A, Cremaschi G, Wald MR. Impaired immune responses in streptozotocin-induced type I diabetes in mice. Involvement of high glucose. Clin Exp Immunol 2008; 154:235246.
  • 24
    Watanabe H, Numata K, Ito T, Takagi K, Matsukawa A. Innate immune response in Th1- and Th2-dominant mouse strains. Shock 2004; 22:460466.
  • 25
    Guiñazú N, Pellegrini A, Giordanengo L et al. Immune response to a major Trypanosoma cruzi antigen, cruzipain, is differentially modulated in C57BL/6BL/6 and BALB/c mice. Microbes Infect 2004; 6:12501258.
  • 26
    Ulett GC, Ketheesan N, Hirst RG. Cytokine gene expression in innately susceptible BALB/c mice and relatively resistant C57BL/6 mice during infection with virulent burkholderia pseudomalle. Infect Immun 2000; 68:20342042.
  • 27
    Roggero E, Pérez AR, Bottasso OA, Besedovsky HO, Del Rey A. Neuroendocrine-immunology of experimental Chagas' disease. Ann NY Acad Sci 2009; 1153:264271.
  • 28
    Autenrieth IB, Beer M, Bohn E, Kaufmann SH, Heesemann J. Immune responses to Yersinia enterocolitica in susceptible BALB/c and resistant C57BL/6 mice: an essential role for gamma interferon. Infect Immun 1994; 62:25902599.
  • 29
    Nishikawa S, Yasoshima A, Doi K, Nakayama H, Uetsuka K. Involvement of sex, strain and age factors in high fat diet-induced obesity in C57BL/6J and BALB/cA mice. Exp Anim 2007; 56:263272.
  • 30
    Herold KC, Baumann E, Vezys V, Buckingham F. Expression and immune response to islet antigens following treatment with low doses of streptozotocin in H-2d mice. J Autoimmun 1997; 10:1725.
  • 31
    Like AA, Rossini AA. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 1976; 193:415417.
  • 32
    Silberman DM, Wald MR, Genaro AM. Acute and chronic stress exert opposing effects on antibody responses associated with changes in stress hormone regulation of T-lymphocyte reactivity. J Neuroimmunol 2003; 144:5360.
  • 33
    Nicolletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139:271279.
  • 34
    Bass DA, Parce JW, Dechatelet LR, Szejda P, Seeds MC, Thomas M. Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J Immunol 1983; 130:19101917.
  • 35
    Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol 1979; 52:302310.
  • 36
    Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 2004; 37:277285.
  • 37
    Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione. Anal Biochem 1968; 27:502522.
  • 38
    Baker MA, Cerniglia GJ, Zaman A. Microtiter plate assay for the measurement of glutathione and glutathione disulfide in large numbers of biological samples. Anal Biochem 1990; 90:360365.
  • 39
    Hadzic T, Li L, Cheng N, Walsh SA, Spitz DR, Knudson CM. The role of low molecular weight thiols in T lymphocyte proliferation and IL-2 secretion. J Immunol 2005; 175:79657972.
  • 40
    Eibl N, Spatz M, Fischer GF et al. Impaired primary immune response in type-1 diabetes: results from a controlled vaccination study. Clin Immunol 2002; 103:249259.
  • 41
    Spatz M, Eibl N, Hink S et al. Impaired primary immune response in type-1 diabetes. Functional impairment at the level of APCs and T-cells. Cell Immunol 2003; 221:1526.
  • 42
    Saiki O, Negoro S, Tsuyuguchi I, Yamamura Y. Depressed immunological defence mechanisms in mice with experimentally induced diabetes. Infect Immun 1980; 28:127131.
  • 43
    Sakowicz-Burkiewicz M, Kocbuch K, Grden M, Szutowicz A, Pawelczyk T. Diabetes-induced decrease of adenosine kinase expression impairs the proliferation potential of diabetic rat T lymphocytes. Immunology 2006; 118:402412.
  • 44
    Stratton IM, Adler AI, Neil HA et al. on behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405412.
  • 45
    Rubinstein MR, Cremaschi GA, Oliveri LM, Gerez EN, Wald MR, Genaro AM. Possible involvement of stress hormones and hyperglycaemia in chronic mild stress-induced impairment of immune functions in diabetic mice. Stress 2010; 13:384391.
  • 46
    Burdon RH. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med 1995; 18:775794.
  • 47
    Franco R, Cidlowski JA. Apoptosis and glutathione: beyond an antioxidant. Cell Death Differ 2009; 16:13031314.
  • 48
    Jones DP. Redefining oxidative stress. Antioxid Redox Signal 2006; 8:18651879.
  • 49
    Yen HC, Li SH, Majima HJ et al. Up-regulation of antioxidant enzymes and coenzyme Q(10) in a human oral cancer cell line with acquired bleomycin resistance. Free Radic Res 2011; 45:707716.
  • 50
    Qi Z, Fujita H, Jin J et al. Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 2005; 54:26282637.